Menu Close

Articles on Pharmaceutical industry

Displaying 1 - 20 of 41 articles

The first Pfizer-BioNTech COVID-19 vaccine dose in Canada sits ready for use at The Michener Institute in Toronto in mid-December 2020, less than a year from when the World Health Organization declared COVID-19 a pandemic. THE CANADIAN PRESS/Frank Gunn

Big Pharma’s COVID-19 reputation boost may not last — here’s why

If Big Pharma wants to achieve the ultimate image makeover, it must capitalize on the current public good will about its COVID-19 vaccines by prioritizing socially responsible practices.
Though drug recalls are relatively uncommon in the U.S., reduced inspections increase the likelihood of manufacturing errors that slip through the cracks. AP Photo/Rafiq Maqbool

The FDA’s weak drug manufacturing oversight is a potentially deadly problem

COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
Anita Anand, Canada’s minister of public services and procurement, opens a box with some of the first 500,000 of the two million AstraZeneca COVID-19 vaccine doses that Canada secured last March through a deal with the Serum Institute of India. THE CANADIAN PRESS/Carlos Osorio - POOL

Canada is virtue signalling while waffling on global access to COVID-19 vaccines

Despite some public virtue signalling, the Canadian government is not doing all it can to improve global access to COVID-19 vaccines. Canada has yet to announce its position on the WTO patent waiver.
A woman who said she’s a medical worker who works directly with COVID-19 patients is stopped by police outside of the public Rebagliati Hospital in Lima, Peru, in February 2021. She complained that some people getting vaccinated don’t work directly with COVID-19 patients. (AP Photo/Martin Mejia)

Peru’s COVID-19 vaccine scandal shows the shady deals made with pharma companies

A vaccination queue-jumping scandal in Peru has caused a massive uproar in the South American country. It could also be a wake-up call for all nations.
Over 90 per cent of Canadian doctors see pharmaceutical sales representatives. (Shutterstock)

Guidelines governing Canadian doctors’ relationships with pharma companies under review

Patients have a stake in the relationship between doctors and pharmaceutical companies, so the CMA’s current review of its guidelines for doctor/pharma interactions is everybody’s business.
Despite monitoring the same drugs, Australia, Canada, the United Kingdom and the United States issued the same drug warnings only seven per cent of the time over a 10-year period. (Pixabay)

Drug Safety: Health Canada must act faster when approved medications show risks

Health Canada devotes far more resources to getting new drugs onto the market compared to making sure that drugs already being sold are safe.
Doctors’ prescribing habits are influenced by drug reps and other industry marketing. Monkey Business Images/Shutterstock

Time to end drug company distortion of medical evidence

Too often, pharmaceutical companies and device manufacturers exert influence in how their products are tested in the research phase and recommended in the clinic.
Tax breaks or exemptions for those working in pharmacy, health insurance and pharmaceutical industries could help bolster support for a national pharmacare plan. (Shutterstock)

Tax breaks could soften the blow of a national pharmacare plan

Two community pharmacists suggest a way for improving the palatability of evidence-based universal pharmacare – for those working in health insurance, pharmacy and the pharmaceutical industry.

Top contributors

More